Table 2. Associations of DCBLD family members with cancer

Data were compiled from primary literature reports.

Cancer typeFamily memberCell type studiedPhenotype/AssociationMolecular insightsReferences
Lung adenocarcinomaDCBLD1Clinical specimensAssociated with EGFR mutationsN/A[36,42]
MyxofibrosarcomaDCBLD2Clinical specimensAssociated with invasive propertiesN/A[34]
Lung cancerDCBLD2Clinical specimens, A549Promotes cell motilityMay interact with SEMA4B[2,3]
NeuroendocrineDCBLD2Clinical specimensInvolved in invasion, progression, metastasisN/A[33]
Glioma, head-and-neck cancerDCBLD2U87, SNB19, PCI-158Required for EGFR-driven tumorigenesis; Associated with poor prognosisEGFR-mediated pTyr750 facilitates TRAF6-mediated Akt activation[5]
GliomaDCBLD1Clinical specimensHigh expressionN/A[43]
Gastric cancerDCBLD2Clinical specimens, SNU-016, SNU-601, SNU-620, SNU-638Inhibits colony formation and invasionHigh promotor methylation[35]
Colorectal cancerDCBLD2Clinical specimens, HT29, RKOReduced in distant metastases; Associated with good prognosisPPARγ and TNF-α signaling regulate NT5E and DCBLD2 levels[40]
MelanomaDCBLD2Clinical specimens, HeLaHigh levels associated with decreased migrationExpression repressed by AP2-alpha[3739]
Cervical cancerDCBLD2A431N/ApTyr target downstream of EGF-signaling[32]
Pancreatic cancerDCBLD2Clinical specimensAssociated with poor survival, vascular invasion, and an aggressive squamous subtypePart of a 5-gene signature with ADM, ASPM, E2F7, and KRT6A[41]